ME: 23andMe Holding Co. Growth-Adjusted Market Cap to Net Income

Cloud IT infrastructure and partner laboratories are optimizing bio-data storage costs for 23andMe Holding Co. (ME). The undervalued growth company indicator captures price action, where the metric remains around 0.00. Management is developing a drug discovery platform leveraging its genetic database. Leadership is currently implementing cost reductions in connection with privatization, which defines the long-term prospects of the biotech firm.

23andMe Inc. (ME): Price/Earnings to Growth Ratio from 07/04/2022 to 04/05/2025

Metric breakdowns and analytics for 23andMe Holding Co. (ME)

- price and consensus price forecast:

Market Chart 23andMe Holding Co|ME - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization 23andMe Inc.|ME - Total Company Value

- company book value details:

Net Assets per Share 23andMe|ME - Company Book Value|Market Cap to Net Assets Ratio 23andme.com|ME - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

ME - Net Income|Expected Net Income 23andMe Holding Co.|ME - P/E Multiple|Future Price to Earnings Multiple 23andMe Inc|ME - Price/Earnings to Growth Ratio|Company Value to EBITDA 23andMe Inc.|ME - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months 23andMe|ME - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months 23andme.com|ME - Earnings growth in current year|Consensus forecast of earnings per share growth for next year 23andMe Holding Co.

- total revenue and sales volume data:

ME - Company Revenue|Company Revenue Forecast 23andMe Holding Co|ME - P/S Multiple|Projected Price to Revenue 23andMe Inc.

General company analysis:23andMe Holding Co (ME)

The PEG ratio measures the relationship between a stock's market value and its earnings growth rate, allowing for the determination of an asset's fair value based on its future expansion. By analyzing the current P/E-to-growth dynamics, an investor can assess the effectiveness of 23andMe Holding Co. (ME) crisis management amid depleting liquidity and the transition from test sales to data monetization.

Competitors of 23andMe Holding Co.